Literature DB >> 1491738

Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology.

M B Schapiro1, J V Haxby, C L Grady.   

Abstract

Recent evidence suggests that Alzheimer's disease is an etiologically heterogeneous disorder. A human model of Alzheimer's disease exists that avoids such problems of etiologic heterogeneity. Down syndrome (DS), trisomy 21, is a genetic disorder in which an extra portion of chromosome 21 leads to mental retardation, short stature, and phenotypic abnormalities. Prior investigations by others have shown that DS subjects over 40 years of age demonstrate neuropathologic and neurochemical defects postmortem that are virtually indistinguishable from those found in brains of Alzheimer's disease patients and a universal cognitive deterioration more severe in demented than nondemented older DS subjects. In our study, these nondemented older DS subjects show a distinctive pattern of age-related deficits, while a more global pattern is seen in demented older DS subjects. Dementia occurs in 40% of older DS subjects. We find that in older demented DS subjects positron emission tomography (PET) shows identical patterns of abnormal glucose metabolism as those described previously in Alzheimer's disease patients, selectively involving the phylogenetically newer association areas of parietal and temporal neocortices but sparing primary sensory and motor regions. Further, we find in older demented DS patients quantitative computer-assisted tomography (CT) indicates accelerated neuronal loss and brain atrophy, similar to that previously shown in Alzheimer's disease patients. As a potential use of the DS model, we observed a case of DS with dementia but without mental retardation. This case suggests that expression of dementia in DS may involve genes on chromosome 21 other than in the "obligatory" distal segment of the q arm. Alternatively, differential expression of genes on the q arm of chromosome 21 might cause dementia without phenotypic features and mental retardation.

Entities:  

Mesh:

Year:  1992        PMID: 1491738     DOI: 10.1016/0197-4580(92)90096-g

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  18 in total

1.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

2.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

3.  Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

Authors:  Linda D Nelson; Prabha Siddarth; Vladimir Kepe; Kevin E Scheibel; S C Huang; Jorge R Barrio; Gary W Small
Journal:  Arch Neurol       Date:  2011-06

4.  Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Authors:  Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Down's syndrome and the links with Alzheimer's disease.

Authors:  A J Holland; C Oliver
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-08       Impact factor: 10.154

Review 6.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

7.  Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.

Authors:  Zhihou Liang; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Jerzy Wegiel; Cheng-Xin Gong
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

Review 8.  The impact of aging on eating, drinking, and swallowing function in people with Down's syndrome.

Authors:  Tracy Lazenby
Journal:  Dysphagia       Date:  2008-03       Impact factor: 3.438

9.  Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.

Authors:  H U Shetty; M B Schapiro; H W Holloway; S I Rapoport
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome.

Authors:  Victoria Fleming; Brianna Piro-Gambetti; Austin Patrick; Matthew Zammit; Andrew Alexander; Bradley T Christian; Benjamin Handen; Annie Cohen; William Klunk; Charles Laymon; Beau M Ances; David T Plante; Ozioma Okonkwo; Sigan L Hartley
Journal:  Neurobiol Aging       Date:  2021-07-29       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.